Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC approves Schick deal

This article was originally published in The Rose Sheet

Executive Summary

Purchase of Pfizer's Schick-Wilkinson Sword razor business by Energizer Holdings approved by FTC, anti-trust enforcers announce Feb. 19. Battery manufacturer recently revealed plan to purchase the business from Pfizer for $930 mil. in a transaction expected to close in the spring (1"The Rose Sheet" Jan. 27, 2003, p. 4). Move will expand Energizer's business beyond batteries and improve its competitive position vis-à-vis Duracell battery manufacturer Gillette, which currently dominates the shaving market with a 70% share...

You may also be interested in...



Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

Commission’s One-Year MDR Delay Text Contains EU-Wide Derogation Proposals Too

The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.

Australia Relaxes Competition Rules To Facilitate Coronavirus Response

Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

UsernamePublicRestriction

Register

RS011009

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel